These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26269456)

  • 1. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression.
    Pignoloni B; Fionda C; Dell'Oste V; Luganini A; Cippitelli M; Zingoni A; Landolfo S; Gribaudo G; Santoni A; Cerboni C
    J Immunol; 2016 Nov; 197(10):4066-4078. PubMed ID: 27733551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 Jul; 30(14):3023-3035. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
    Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
    J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
    Cippitelli M; Stabile H; Kosta A; Petillo S; Gismondi A; Santoni A; Fionda C
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
    J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.
    Fionda C; Abruzzese MP; Zingoni A; Soriani A; Ricci B; Molfetta R; Paolini R; Santoni A; Cippitelli M
    BMC Cancer; 2015 Jan; 15():17. PubMed ID: 25609078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.